Press Release Oct 01 2022
Filed with NSE · · 2 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited has issued a press release announcing that it received final approval from the USFDA for Sildenafil for Oral Suspension. This medication is intended for treating pulmonary hypertension by relaxing blood vessels in the lungs. The drug will be produced at the company's facility in Baddi, Himachal Pradesh, India.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Sep 20 2022
- Press Release Sep 16 2022
- Press Release Sep 13 2022
- Press Release Sep 12 2022
- Press Release Sep 09 2022
Later from Zydus Lifesciences
- Press Release Oct 03 2022
- Press Release Oct 04 2022
- Press Release Oct 06 2022
- Zydus Lifesciences: General updates
- Press Release Oct 17 2022
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences